Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience
CI demonstrated significant improvements in MG-ADL and QMG scores, along with a steroid-sparing effect, suggesting its potential as an effective treatment for this challenging subpopulation.
Authors
- Raffaele Iorio (ORCID: https://orcid.org/0000-0003-1599-7096)
- Elena Rossini (ORCID: https://orcid.org/0009-0002-7862-6743)
- Laura Fionda (ORCID: https://orcid.org/0000-0002-8813-2272)
- Sofia Marini
- Elisa Meacci (ORCID: https://orcid.org/0000-0001-7189-5903)
- Francesco Habetswallner
- Carmen Erra (ORCID: https://orcid.org/0000-0002-8001-0836)
- Silvia Falso
- Martina Marini
- Federico Habetswallner
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Ospedale Antonio Cardarelli (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1562419
- Citations
- 3
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 4.17
Funders
- Rare Diseases Clinical Research Network
- Ministero della Salute
- National Institutes of Health